focus -WSS

focus

author：Wikipedia 2025-10-04 12:05:22 Page View：9

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Woodcock on FDA’s accelerated approval and her next chapter
Next article： Psychedelics group wrestles with new pharma identity

comprehensive

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

In early work, researchers turn to CRISPR to treat Alzheimer's

AdobeWhenthegenome-editingtoolCRISPRisthoughtofasapotentialmedicine,thetargetsthatfirstcometomindare

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Some dementia cases could be undiagnosed liver disease

AdobeThedescentintodementiacanfeelliketraversingaminefield,comingacrossnewsymptomswithoutthehopeofac

focus

leisure time

comprehensive

Some dementia cases could be undiagnosed liver disease